

Advanced Control Specialty Formulary®

January 2023 Updates

Removals	Add-Backs
11	4

Removals

Drug Class	Removed Product(s)	Formulary Options
Anti-Inflammatory, Cryopyrin-Associated Periodic Syndromes (CAPS)	ARCALYST	ILARIS
Asthma, Severe	NUCALA LYOPHILIZED	DUPIXENT, FASENRA, NUCALA (except lyophilized powder), TEZSPIRE, XOLAIR
Cancer, Poly-ADP Ribose Polymerase (PARP) Inhibitors	RUBRACA	LYNPARZA, ZEJULA
Cancer, Renal Cell Carcinoma*	SUTENT**, VOTRIENT	sunitinib, CABOMETYX, INLYTA, LENVIMA, NEXAVAR
Endocrine, Metabolic Modifiers	NITYR	ORFADIN
Hematologic, Hemophilia B*	BENEFIX, IXINITY, RIXUBIS	ALPROLIX, REBINYN
Hereditary Angioedema	FIRAZYR**	icatibant, RUCONEST
Pulmonary Fibrosis Agents	ESBRIET	pirfenidone, OFEV

Add-Backs

Drug Class	Product(s) Added Back
Autoimmune Agents*	ILUMYA
Cancer, Follicular Lymphoma Phosphatidylinositol-3-kinase (PI3K) Inhibitors*	ZYDELIG
Hematologic, Hemophilia B*	ALPROLIX
Thrombocytopenia Agents	MULPLETA (non-preferred)

New to Market Updates

Indication	Product(s) Added
Asthma, Severe	TEZSPIRE
Atopic Dermatitis	ADBRY, CIBINQO
Cancer, Rearranged During Transfection (RET) Inhibitors	GAVRETO, RETEVMO

Indication-Based Strategy Updates

Indication	Product(s) Added
Ulcerative Colitis	RINVOQ, XELJANZ, XELJANZ XR – Removal of step edit through HUMIRA

*Class has existing formulary exclusions. **Multi-source Brand Product

This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Removals and Add-Backs as of September 29, 2022. Information subject to change.

©2022 CVS Health and/or its affiliates. All rights reserved. 106-54612B 092622